anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a plaster for promoting subsidence of swelling and dissipating blood stasis, and a preparation method thereof, relating to a plaster and a preparation method thereof. The invention aims at solving the problems of irritation, allergy and slowness in promoting subsidence of swelling, dissipating blood stasis and recovering caused by the existing chemical medicinal plasters, and pollution of an affected part caused by applying sliced potatoes. The plaster for promoting subsidence of swelling and dissipating blood stasis comprises potato extract, an adhesive tape, a medicinal core and a cover layer. The preparation method of the plaster for promoting subsidence of swelling and dissipating blood stasis comprises the following steps of: extracting potatoes by an ethanol or vitamin C solution, filtering and concentrating to obtain extract; weighing the extract, mixing with water to obtain a potato extract solution; soaking a non-woven fabric or purified cotton fabric tape into the extract solution, drying to obtain the medicinal core; and fixing the medicinal core on the substrate adhesive tape, and attaching the cover layer to obtain the plaster for promoting subsidence of swelling and dissipating blood stasis. The plaster for promoting subsidence of swelling and dissipating blood stasis provided by the invention has no irritation and allergy to skin, shortens the time for promoting subsidence of swelling, dissipating blood stasis and recovering, and solves the problem of inconvenience in applying fresh sliced potatoes. The product provided by the invention is used for preventing and treating gore, swelling, pain and induration caused by injection, drip and trauma.
In this study, we adopted a 3+3 design with dose escalation. Initially, three dose groups were established: 2.0×10\^7, 6.0×10\^7, and 2.0×10\^8 cells/kg. Each dose group received treatment on Days 0, 3, and 6 through i.v. injection, with bone marrow examination performed on Day 7 to assess tumor burden. Upon assessment by the investigators and discussion with the Safety Review Committee (SRC), it will be determined that whether patients may benefit from additional infusions. With SRC approval, the number of administrations could be increased, not exceeding a maximum of six doses. At the end of dose escalation, the SRC may decide to adjust the number of participants in the designated dose group as deemed appropriate.
Anemia has occurred in NSAID-treated patients. This may be due to occult or gross blood loss, fluid retention, or an incompletely described effect upon erythropoiesis. If a patient treated with VIVLODEX has any signs or symptoms of anemia, monitor hemoglobin or hematocrit.

NSAIDs, including VIVLODEX, may increase the risk of bleeding events. Concomitant use of warfarin and other anticoagulants, antiplatelet agents (e.g., aspirin), and serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk. Monitor these patients for signs of bleeding [see Drug Interactions (7)].
The invention belongs to the technical field of medicine and relates to coenzyme Q10 nanosuspension freeze-dried compositions of different particle sizes and a preparation method and application thereof. The composition comprises coenzyme Q10, a surfactant and a caffolding agent. According to a formula, the composition consists of the following components in percentage by mass: 0.02-2 percent of coenzyme Q10, 0-5 percent of surfactant, 0-20 percent of caffolding agent, 1-30 percent of organic solvent and the balance of water. A coenzyme Q10 nanosuspension has stable mass, and preparations of which the particle sizes are between 80 nanometers and 10 mum can be prepared. The invention has the characteristics of convenience for administration, definite dosage, increase in the dissolution rate of a medicament, higher bioavailability and the like. According to the invention, coenzyme Q10 can fully play a medicinal role in health-care medicaments and disease treatment.
Breast cancer (BC) is the most common malignancy in women in western countries. A significant part of malignant cases is caused by genetic mutation. Mutations in the gene phosphatase and tensin homologue deleted on chromosome (PTEN) have been proven in various malignancies. The present study was conducted with the aim of investigating the prevalence of BC due to PTEN gene mutation, as well as estimating the chance of developing BC due to the occurrence of PTEN gene mutation. The present study was conducted using a systematic review method based on PRISMA 2020 statements. The search was done in PubMed, Web of Science (WOS), Scopus, and direct scientific databases. The search was performed using the keywords breast cancer, breast malignancy, PTEN, polymorphism, mutation, variant, and their equivalents. Statistical analysis was performed using the second version of Comprehensive Meta-Analysis Software. A total of 2138 articles were collected. After removing duplicate articles, checking the title and abstract, and then checking the full text of the documents, finally 64 articles were approved and entered the systematic review process. Analysis of these studies with a sample size of 231,179 showed the prevalence of breast cancer patients with PTEN mutations. The combined results of 64 studies showed that the prevalence of PTEN mutations has a 3.3 (95% CI 2.2-5) in BC patients, and an analysis of 6 studies showed that the odds ratio of developing BC due to PTEN mutation is 3.7 (95% CI 1.1-11.9). The results of this study show that mutation in the PTEN gene increases the chance of developing BC. However, it was found that a small part of patients gets BC due to the occurrence of mutation in this gene.
BACKGROUND Heyde syndrome is characterized by anemia due to angiodysplasia, aortic valve stenosis, and acquired von Willebrand syndrome. However, the awareness regarding Heyde syndrome in clinical practice is low. We report the case of an older woman with severe refractory iron-deficiency anemia and severe aortic stenosis who was diagnosed with Heyde syndrome. CASE REPORT A 70-year-old woman who had been experiencing exertional dyspnea for 3 months prior to presentation was diagnosed with iron-deficiency anemia, with a hemoglobin level of 69 g/L. She did not experience any episodes of bleeding, such as nosebleeds, gum bleeding, abnormal bleeding, or melena. Upper and lower gastrointestinal endoscopy revealed no evidence of bleeding, and oral iron supplementation failed to improve the anemia. Auscultation of the chest identified an ejection systolic murmur. Chest and abdominal computed tomography showed no significant lesions or active bleeding. Capsule endoscopy of the small intestine revealed capillary dilation. Echocardiography detected severe aortic valve stenosis. Blood test results revealed a deficiency in large von Willebrand factor multimers. Therefore, Heyde syndrome was diagnosed. Aortic valve replacement surgery was performed, which resulted in an improvement in anemia and the associated symptoms. CONCLUSIONS In cases of unexplained and treatment-resistant iron-deficiency anemia, especially if careful auscultation detects aortic stenosis, Heyde syndrome should be considered a differential diagnosis. Furthermore, screening for angiodysplasia in the gastrointestinal tract and prompt diagnosis through measurement of large von Willebrand factor multimers are imperative when investigating potential sources of bleeding.
ICA built from participants from two RCTs called FIDELIO-DKD and FIGARO-DKD pooled for the FIDELITY analyses. FIDELIO-DKD/FIGARO-DKD placebo controls treated with SGLT2is at baseline.
In the audio intervention, participants will complete the scheduled module 5 times a week of the intervention. The content is similar to that of the VR, which will be delivered by the audio player. Each session varies in duration approximately from 3 to 15 minutes.
The presence of comorbidities (CM) in congenital lobar emphysema (CLE) has been previously described with varying rates. However, the clinical implication of CM on the clinical presentation and patient outcome in CLE is unclear. This was a retrospective cohort study between 2000 and 2022 in a single institution. The study included pediatric patients diagnosed with CLE. During the study period, 36 patients were identified with CLE. The presence of respiratory symptoms at diagnosis was documented in 69% (24/35) of the patients with 48% admitted to intensive care units. The presence of CM was documented in 14/36 (39%) of the patients, with cardiovascular anomalies as the most common (22%), followed by genitourinary anomalies (11%) and large airway anomalies (8%). When comparing the CM group (n = 14) vs the non-CM group (N = 22), there was no significant difference regarding gender, term birth, age of diagnosis, and the location of the lesion. The CM group had significantly higher rates of intensive care unit (ICU) admissions (75% vs 33%, p = 0.02), longer duration of admission (median 46 days vs 9, p = 0.02), and need for pre-operative non-invasive respiratory support (50% vs 5%, p = 0.002).Conclusion: The presence of CM in CLE was associated with a more severe presentation as reflected with significantly higher rates of ICU admissions, prolonged admissions, and higher need for non-invasive respiratory support. Screening for CM, mostly for cardiac anomalies, is recommended at time of CLE diagnosis. What is Known: • Congenital lobar emphysema (CLE) is a developmental lung anomaly generally associated with other comorbidities; however, their clinical implication on presentation is unclear • The prevalence of comorbidities in CLE was previously reported around 15-20%, with cardiovascular anomalies as the most common What is New: • Comorbidities are very common (39%) in CLE, and their presence is related to a more severe clinical presentation and need for respiratory support • Screening for comorbidities is recommended in CLE, specifically for cardiovascular and genitourinary anomalies.
PURPOSE:To obtain a W/O emulsion composition extremely stable over a wide temp. range, by using a propylene oxide/ethylene oxide adduct having a propylene oxide chain present therein and containing an alkyl group as branched group. CONSTITUTION:A propylene oxide/ethylene oxide adduct [e.g., polyoxyethylene (15)polyoxypropylene(8)-2-tetradecyl-octadecyl ether] represented by formula (wherein a is an integer of 7-19, b is an integer of a+2, m is a number of 5- 30 in an average addition mol number and n is a number of 5-30 in an average addition mol number) is contained in an amount of 0.1-20wt% of the total amount of a W/O emulsion composition. This W/O emulsion composition has extremely good storage stability over a wide temp. range. Especially, polar oil such as triglyceride being a sebum analogue component, which could not be compounded conventionally even if desired to be compounded because stability at ambient temp. was inferior, can be prepared as an extremely stable W/O emulsion composition.
PROBLEM TO BE SOLVED: To obtain a hair cosmetic which can prevent hair from damaging caused by ultraviolet ray and the like and is useful for the hair oil and the shampoo capable of preventing hair from drying even in the strong damage by formulating a specific amide compound with an ultraviolet absorber. SOLUTION: This hair cosmetic is obtained by formulating (A) an amide compound (e.g. a compound of the formula and the like) such as a N-substituted amide and the like which shows a melting point of 0-50 deg.C and possesses the total carbon atoms of preferably 30 or more and at least 5 wt.% of bound water capable of being held with (B) an ultraviolet absorber such as octyl methoxycinnamate preferably in proportions of 0.1-20 wt.% of the compound A and 0.05-10 wt.% of the component B in the whole composition. In addition, it is preferable that a plant, e.g. Sesamum indicum L. and the like, its extract or its pressed product is formulated thereto. This cosmetic can prevent the surface oxidation of hair and the change in the color tone and is useful for a hair mousse, a hair conditioner and a linse.
Children with moderate to severe TBI are at risk of significant long-term neurological sequelae. Careful post-injury management is crucial in optimizing their recovery. Seizures are a frequent complication. They are associated with worse outcome and require prompt intervention. However, they are often subclinical and are only detectable by gold-standard conventional electroencephalography (cEEG); a costly, complex monitoring device that is not readily available 24/7 in many pediatric intensive care units (PICUs) and can only be interpreted by neurologists. On average, PICUs obtain only 1-2 cEEG reports per day from neurologists and this can lead to significant delays in seizure identification and treatment. Amplitude-integrated EEG (aEEG) is a compressed form of real-time cEEG monitoring that can be added to cEEG monitoring. It is more easy to interpret and can be taught to PICU providers with limited training. It is a promising complementary tool that could help PICU physicians identify subclinical seizures and treat seizures more promptly. This could significantly improve the global outcome of this vulnerable population.
Cutaneous squamous cell carcinoma (cSCC) is the second most prevalent form of skin cancer, with an escalating incidence rate and a notable potential (up to 5%) for metastasis. Ultraviolet radiation (UVA and UVB) exposure is the primary risk factor for cSCC carcinogenesis, with literature suggesting ultraviolet radiation (UVR) promotes vascular endothelial growth factor A (VEGFA) expression. This study aims to investigate UVR-induced upregulation of VEGFA and explore combination therapeutic strategies. The skin squamous cell carcinoma cell line A431 was exposed to specific durations of ultraviolet radiation. The effect of emodin on ATR/SerRS/VEGFA pathway was observed. The cell masses were also transplanted subcutaneously into mice (n = 8). ATR inhibitor combined with emodin was used to observe the growth and angiogenesis of the xenografts. The results showed that UV treatment significantly enhanced the phosphorylation of SerRS and the expression level of VEGFA in A431 cells (p < 0.05). Treatment with emodin significantly inhibited this expression (p < 0.05), and the combination of emodin and ATR inhibitor further enhanced the inhibitory effect (p < 0.05). This phenomenon was further confirmed in the xenograft model, which showed that the combination of ATR inhibitor and emodin significantly inhibited the expression of VEGFA to inhibit angiogenesis (p < 0.05), thus showing an inhibitory effect on cSCC. This study innovatively reveals the molecular mechanism of UV-induced angiogenesis in cSCC and confirms SerRS as a novel target to inhibit cSCC angiogenesis and progression in vitro and in vivo studies.
This is an open-label (name of assigned treatment is known), single-center study of the pharmacokinetics (blood levels) and safety of 3 single doses of methylphenidate HCl administered orally (by mouth) to healthy Japanese adult male volunteers. Methylphenidate HCl is a drug that is currently approved for the treatment of adults with attention-deficit/hyperactivity disorder (ADHD) in regions outside Japan, including the United States where this study will be conducted. Volunteers will participate in the study for a maximum of 42 days. Blood samples will be collected from volunteers during the study to determine the concentration of the methylphenidate HCl in the blood after dosing. Safety will be monitored throughout the study by evaluating adverse events reported, changes in clinical laboratory test results, vital signs measurements, physical examination results, and other protocol-specified safety assessments. All volunteers will receive a single oral dose of methylphenidate HCl with 240 mL (1 cup) of noncarbonated water after at least a 10-hour fast (without eating food) during 3 treatment periods as follows: Period 1, one 36-mg tablet; Period 2, three 18-mg tablets; and Period 3, two 36-mg tablets. Treatment periods will be separated by 3 to 7 days. Volunteers will continue fasting until at least 4 hours after dosing.
A magnetic, thermosensitive, fluorescent micelle includes a core, a carrier wrapping the core, and a plurality of water-soluble near-infrared CdHgTe quantum dots (QD) disposed on the carrier. The core includes dextran-magnetic layered double hydroxide-fluorouracil (DMF). The carrier includes a tripolymer of poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-polylactic acid (PLA). N-isopropylacrylamide-co-N,N-dimethylacrylamide of the tripolymer includes a hydrophilic group and a hydrophobic carbon frame. The hydrophilic group is oriented outwards with respect to the and forms a shell. The hydrophobic carbon frame and polylactic acid are restrained to wrap the dextran-magnetic layered double hydroxide-fluorouracil to form the core.
Lingual orthodontic appliances provide an ultimate esthetic solution for patients who do not want visible orthodontic appliances. Recently, lingual orthodontic treatment outcomes have become similar and comparable to those produced with labial orthodontic treatment. However, placement of orthodontic brackets on the lingual surfaces of teeth causes changes in their morphology, which results in articulation problems, chewing difficulties, tongue irritation and other impairments. In this respect, the main difference between the labial and lingual techniques is the distance between the point of application of the force that is transmitted through the bracket and the centre of resistance of the tooth. Consequently, the displacement and stress induced in bone by these two techniques will also differ, and these need to be evaluated so that useful comparisons can be made between these two techniques. Patients who have moderate crowding that could be treated without extraction will be treated in this study using either lingual or labial fixed orthodontic appliances. All patients will receive a cone-beam computed tomography (CBCT) scan in two different times (T0: before treatment, T1: after treatment). The dentoalveolar changes will be assessed.
FIELD: medicine, pulmonology, phytotherapy, pharmacy. SUBSTANCE: invention relates to design vegetable species that can be used for treatment of patients with acute and chronic inflammatory diseases of lung, upper respiratory ways, bronchial asthma. Medicinal plant species has plantain leaves, dandelion roots, dioecious nettle herb, thyme herb, marjoram herb and sage herb taken in the definite ratio of components. Proposed species stimulates sputum dilution, improves lung tissue microcirculation, normalizes function of smooth muscles of bronchi. EFFECT: enhanced curative effectiveness of species. 1 cl, 2 ex
The present invention provides a squalene compound agent with the functions of fatigue resistance and aging delaying, which belongs to the technical field of health-care foods. The squalene compound agent of the present invention comprises shark liver oil, soybean lecithin, royal jelly, ginseng and hydrogenated soybean oil. The squalene compound agent of the present invention does not have toxicity. After being taken by human bodies, physical fitness index, the reaction function of three nerves and lung function are enhanced in different extents; high-density lipoprotein is increased obviously, and low-density lipoprotein is reduced obviously. A person taking the squalene compound agent can obviously feel invigorating in spirit, work vigor is vigorous, and appetite and sleep are improved. The present invention also provides a preparation method of the squalene compound agent.
PURPOSE: A transcription inhibitor with a fusion protein having a protein transduction domain and a DNA binding domain of GATA family is provided to inhibit main transcription process. CONSTITUTION: A transcription inhibitor has a fusion protein containing a DNA binding domain of GATA family and a protein transduction domain. The protein transduction domain includes Hph-1, Mph-1, Sim-2, Tat, VP22, Antp(Antennapedia), Pep-1(peptide), PTD-5, 11R(arginine), 7R or CTP(cytoplamic transduction peptide). The protein transduction domain has a sequence of sequence number 1. The DNA binding domain has a sequence of sequence number 2. A pharmaceutical composition for treating autoimmune diseases contains the fusion protein and pharmaceutically acceptable excipient.
Chronic rhinosinusitis (CRS) with (w) and without (s) nasal polyps (NP) in its different shapes is currently affecting up to 16% of the total population of the United States and around 11% of the population in Europe. However CRS may also be associated with hypersensitivity to aspirin and other non-selective cyclooxygenase inhibitors. This syndrome of combined CRSwNP, asthma and intolerance to inhibitors of the cyclooxygenase-1 enzyme was termed Samter's triad or aspirin-exacerbated respiratory disease (AERD). AERD is thought to affect around 16% of patients suffering from CRSwNP, around 7% of adult asthmatic patients and 0.3-2.5% of the general population. One characteristic feature of this disease is the presence of nasal polyps that frequently relapse after surgery rendering this disease difficult to manage. Despite its relatively high prevalence, the pathophysiologic mechanisms are yet not fully understood. In this respect, an overproduction of and overresponsiveness to cysteinyl leukotrienes accompanied by and underproduction of and underresponsiveness to prostaglandins was observed in AERD patients.This indicates a dysregulation of pro and anti-inflammatory pathways. However the mechanism and the cells involved in causing this imbalance are still not clear.

The availability of gene-chip microarray technology allows for quantitatively and simultaneously monitoring of the expression of thousands of genes and has greatly contributed to the understanding of pathological mechanisms. In this context, analysis of nasal polyps from allergic patients has shown that genes involved in deregulated cell growth similar to neoplastic growth are upregulated in this tissue. Furthermore very recently, profiling of CRS samples by single-cell RNA sequencing revealed a significant loss of epithelial ecological diversity in nasal polyps. The authors suggest that basal cells form memories of chronic exposure to an inflammatory environment and shift the cellular ecosystem towards propagating the disease. However polyps from AERD patients which show a different clinical and most likely also pathophysiological profile have not been included in this study. Given the prevalence of 15% amongst CRSwNP patients and the impaired quality of life of AERD patients it would be desirable to understand the difference between AERD and CRSwNP without AERD at a molecular level and also to potentially find biomarkers that uniquely identify patients suffering from AERD disease.

Therefore, the investigators plan to prospectively collect blood samples, nasal secretions as well as nasal biopsies from allergic, non-allergic and AERD patients suffering from CRSwNP. Initially, RNA sequencing will be performed using microarray technology in biopsies of those patients. Once parameters are identified, the investigators will investigate if a similar pattern can also be detected in nasal secretions and/or serum of the respective patients to investigate their potential as biomarkers. Furthermore presence of these parameters will be confirmed in situ in biopsies by confocal microscopy.